Biotech stocks had a particularly rough start to 2016. But the coming week will be a far more informative gauge of the sector’s health.
The Nasdaq Biotechnology Index is now off 10% to start the year, and down nearly 25% from the record high of last July. Part of the selloff is due to global turmoil the past week; while what happens in China has little to do with U.S. biotech companies’ operating prospects, stress in world markets can be problematic for high-risk sectors like biotech.
